FMP
Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
32.72 USD
0 (0%)
HRMY Financial Statements
Year
2024
2023
2022
2021
Current Assets
579.25M
451.07M
400.29M
284.44M
Cash & Short Term Investments
467.19M
353.46M
323.12M
234.31M
Cash And Cash Equivalents
453M
311.66M
243.78M
234.31M
Short Term Investments
14.19M
41.8M
79.33M
0
Net Receivables
83.03M
74.14M
54.74M
34.84M
Inventory
7.2M
5.36M
4.3M
4.43M
Other Current Assets
8.12M
5.54M
8.79M
3.22M
Non-Current Assets
419.95M
360.38M
273.58M
149M
Property, Plant & Equipment
1.26M
371k
573k
820k
Goodwill And Intangible Assets
113.26M
137.11M
160.95M
143.92M
Goodwill
0
0
0
0
Intangible Assets
113.26M
137.11M
160.95M
143.92M
Long Term Investments
108.87M
72.17M
22.57M
750k
Tax Assets
190.4M
144.16M
85.94M
-750k
Other Non-Current Assets
6.16M
6.57M
3.55M
4.26M
Other Assets
0
0
0
0
Total Assets
999.2M
811.45M
673.87M
433.44M
-
-
-
-
Current Liabilities
175.08M
163.78M
78.88M
53.77M
Accounts Payable
13.74M
17.73M
3.79M
1M
Short Term Debt
16.25M
15M
2M
2M
Tax Payables
0
0
0
0
Deferred Revenue
0
0
0
49.41M
Other Current Liabilities
145.09M
107.3M
1.62M
41.61M
Total Current Liabilities
175.08M
163.78M
78.88M
53.77M
Total Non-Current Liabilities
164.96M
180.68M
192.15M
193.16M
Long-Term Debt
0
178.57M
189.65M
189.98M
Deferred Revenue
0
0
0
0
Deferred Taxes Liabilities
0
0
0
0
Other Non Current liabilities
164.96M
2.11M
2.5M
3.18M
Total Liabilities
340.05M
344.46M
271.03M
246.94M
Other Liabilities
0
0
0
0
Stockholders Equity
659.15M
466.99M
402.84M
186.51M
Common Stock
1k
1k
1k
1k
Retained Earnings
2.22M
-143.28M
-272.13M
-453.6M
Accumulated Other Comprehensive Income/Loss
66k
2k
-151k
-0
Other Shareholders Equity
656.87M
0
0
0
Total Liabilities and Stockholders Equity
999.2M
811.45M
673.87M
433.44M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-143.28M
-272.13M
-453.6M
-488.19M
Net Income
145.49M
128.85M
181.47M
34.6M
Stock Repurchases
0
-100M
0
0
Dividend Paid
0
0
0
0
Retained Earnings
2.22M
-143.28M
-272.13M
-453.6M
Other Distributions
145.49M
28.85M
181.47M
34.6M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
1.26M
371k
573k
820k
Annual Depreciation
24.11M
24.36M
23.39M
18.84M
Capital Expenditure
-1.15M
-312k
-40.17M
-100.3M
Net PPE
-21.7M
-23.68M
17.36M
82.28M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
